Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Author(s):
McInnes, I.B.; Sieper, J.; Braun, J.; Emery, P.; Heijde, D. van der; Isaacs, J.D.; Dahmen, G.; Wollenhaupt, J.; Schulze-Koops, H.; Kogan, J.; Ma, S.L.; Schumacher, M.M.; Bertolino, A.P.; Hueber, W.; Tak, P.P.
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-02-28
Language
English
Is part of
Annals of the Rheumatic Diseases (2014), Vol. 73, no. 2, p. 349-356
hdl
1887/103657
doi
10.1136/annrheumdis-2012-202646